Therapeutic vaccines against tuberculosis: A glowing future;Vacuna terapéutica antituberculosa: Un "rutilante" futuro

Archivos de Bronconeumologia

Volumn 43, Issue 11, 2007, Pages 591-593

  Cardona, Pere Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

EDITORIAL; GRANULOMA; HUMAN; MYCOBACTERIUM TUBERCULOSIS; RESUSCITATION; TISSUE NECROSIS; TREATMENT DURATION; TUBERCULOSIS;

EID: 37849006496     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S1579-2129(07)60134-7     Document Type: Editorial

References (32)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva: WHO; 2006.
2. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med. 2000;161:S221-S47.
3. Cardona PJ. New insights on the nature of latent tuberculosis infection and its treatment. Inflamm Allergy Drug Targets. 2007; 6:27-39.
4. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J Clin Microbiol Infect Dis. 1994;13:908-14.
5. Grange JM. Immunophysiology and immunopathology of tuberculosis. En: Davies PDO, editor. Clinical tuberculosis. London: Chapman & Hall; 1998. p. 113-27.
6. Ulrichs T, Kaufmann SH. New insights into the function of granulomas in human tuberculosis. J Pathol. 2006;208:261-9.
7. Barry CE III. Preclinical candidates and targets for tuberculosis therapy. Curr Opin Investig Drugs. 2001;2:198-201.
8. Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin Microbiol Rev. 2001;14:727-52.
9. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-20.
10. Shleeva MO, Bagramyan K, Telkov MV, Mukamolova GV, Young M, Kell DB, et al. Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology. 2002;148:1581-91.
11. Rooney SA, Young SL, Mendelson CR. Molecular and cellular processing of lung surfactant. Faseb J. 1994;8:957-67.
12. Gomes MS, Paul S, Moreira AL, Appelberg R, Rabinovitch M, Kaplan G. Survival of Mycobacterium avium and Mycobacterium tuberculosis in acidified vacuoles of murine macrophages. Infect Immun. 1999;67:3199-206.
13. Boros DL. The cellular immunological aspects of the granulomatous response. En: Boros DL, editor. Granulomatous infections and inflammations. Cellular and molecular mechanisms. Vol. 1. Boros DL, editor. Washington DC: ASM Press; 2003. p. 1-20.
14. D'Avila H, Melo RC, Parreira GG, Werneck-Barroso E, Castro-Faria-Neto HC, Bozza PT. Mycobacterium bovis bacillus Calmette-Guerin induces TLR2-mediated formation of lipid bodies: intracellular domains for eicosanoid synthesis in vivo. J Immunol. 2006;176:3087-97.
15. Andersen P. Host responses and antigens involved in protective immunity to Mycobacterium tuberculosis. Scand J Immunol. 1997;45:115-31.
16. Cardona PJ, Gordillo S, Díaz J, Tapia G, Amat I, Pallarés A, et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun. 2003;71: 5845-54.
17. Brugmann WB, Firmani MA. Low concentrations of nitric oxide exert a hormetic effect on Mycobacterium tuberculosis in vitro. J Clin Microbiol. 2005;43:4844-6.
18. Strickland D, Kees UR, Holt PG. Regulation of T-cell activation in the lung: alveolar macrophages induce reversible T-cell anergy in vitro associated with inhibition of interleukin-2 receptor signal transduction. Immunology. 1996;87:250-8.
19. Roth P, Celada A, Cruchaud A. Evaluation of human monocyte function in vitro. Ann Immunol (Paris). 1979;130C:611-20.
20. Ordway D, Henao-Tamayo M, Orme IM, González-Juarrero M. Foamy macrophages within lung granulomas of mice infected with Mycobacterium tuberculosis express molecules characteristic of dendritic cells and antiapoptotic markers of the TNF receptor-associated factor family. J Immunol. 2005;175:3873-81.
21. Wallace JG. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis. 1961;83:866-71.
22. Bui TD, Dabdub D, George SC. Modeling bronchial circulation with application to soluble gas exchange: description and sensitivity analysis. J Appl Physiol. 1998;84:2070-88.
23. Rieder HL. Epidemiologic basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lund Disease; 1999.
24. Garton NJ, Christensen H, Minnikin DE, Adegbola RA, Barer MR. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology. 2002;148:2951-8.
25. Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J. 2004;24:1044-51.
26. Pérez-Padilla R, Franco-Marina F. The impact of altitude on mortality from tuberculosis and pneumonia. Int J Tuberc Lung Dis. 2004;8:1315-20.
27. Vargas MH, Furuya ME, Pérez-Guzmán C. Effect of altitude on the frequency of pulmonary tuberculosis. Int J Tuberc Lung Dis. 2004;8:1321-4.
28. Cardona PJ, Julián E, Valles X, Gordillo S, Muñoz M, Luquin M, et al. Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis. Scand J Immunol. 2002;55:639-45.
29. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, Díaz J, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine. 2005;23:1393-8.
30. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb). 2006;86:273-89.
31. Cardona PJ, Amat I. Origen y desarrollo de RUTI, una nueva vacuna terapéutica contra la infección por Mycobacterium tuberculosis. Arch Bronconeumol. 2006;42:25-32.
32. Guirado E, Amat I, Gil O, Díaz J, Arcos V, Cáceres N, et al. Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice. Microbes Infect. 2006;8: 1252-9.